Sosei Heptares, a biopharmaceutical company, is poised to reclaim full ownership of its promising drug candidate GSK43814061, intended for the treatment of inflammatory bowel...
GSK's Blenrep, a treatment for multiple myeloma, has shown improved progression-free survival rates in a phase III trial, according to the latest results released today. The...
GSK has disclosed encouraging results from its phase III DREAMM-7 trial, revealing that Blenrep (belantamab mafodotin) has shown effectiveness as a second-line treatment for...
GSK plc (NYSE: GSK) announced headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase 3 trial evaluating belantamab mafodotin as a second-line...
Sosei Heptares, a biopharmaceutical company with operations in Tokyo and Cambridge, is facing a significant shift in its partnership with pharmaceutical giant GSK. GSK announced it...
GSK PLC has announced its commitment to a more sustainable future with the development of a new Ventolin inhaler propellant set to reduce greenhouse gas emissions by approximately...
British pharmaceutical company GSK has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for...
GSK Consumer Nigeria has reported a 7% drop in profit after tax for the nine-month period ending September 30, 2023, amid challenging market conditions and foreign exchange issues....
Pharmaceutical giant GSK Plc has announced an investment of $20 million in 23andMe Holding Co., marking an extension of their five-year collaboration. The investment grants GSK a...
You are right. Also the price has been range bound for a decade and we are now near to the lower bound. I've heard similar comments to you nearly ever year when it's price is underperforming
0
I wish the institutional shareholders would wake up and do something about the management team. Surely with such an abysmal performance over so long GSK must be a takeover target?
0
I'm only interested in swing trading this counter. If the price doesn't move I'll just collect dividends while waiting for it to bounce. The spinoff of Haleon is a good move as in this day and age companies need to be pure play to get ahead of competition. Consumer healthcare business was a distraction to their management.
0
new management required
0
Bloodbath coming
3
Hi John, it will be worsth ?
0
When will this carnage start, exacty (02/11/22)
0
Should have taken the Unilever offer...
0
It was madness not to.
0
Demerger yet another damp squib in a long line of failures by Walmsley. She is unprecedented in her ability to talk the talk but to not walk the walk!
2
This may go up further but I've started to take some profit as precaution. I suspect ulvr may not revise their offer after its sp tanking showing clear sentiments from shareholding to reject this move